VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?

September 23, 2026 - 09:02

Viking Therapeutics has seen its stock outperform major competitors Eli Lilly and Novo Nordisk this month after releasing promising data on its experimental obesity treatment. The results have sparked discussion about whether the company's drug candidate could eventually challenge established products like Wegovy and Zepbound.

Obesity specialist Lou Aronne noted that patients switching from a single GLP-1 drug to a dual GLP-1/GIP drug could experience greater weight loss. This observation is particularly relevant as Viking's treatment targets both hormone pathways, similar to Lilly's Zepbound but with its own distinct molecular profile.

The data release has energized investors who see Viking as a potential disruptor in the rapidly growing weight loss market. Lilly and Novo Nordisk currently dominate the space, but Viking's early results suggest the company may have a competitive asset on its hands.

Whether Viking can win over existing Wegovy and Zepbound users remains an open question. Switching treatments involves discussions with physicians, insurance coverage considerations, and patient comfort with new options. Still, the prospect of improved efficacy could drive interest if larger trials confirm the initial findings.

Viking has not yet announced a timeline for late stage trials or regulatory submissions. Analysts caution that early data often does not guarantee final approval or commercial success. For now, the stock movement reflects optimism that a third strong player may soon enter the obesity treatment landscape.